News & Events

Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer

Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer

ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer

ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

Adagrasib (Krazati; MRTX849): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Cancers

Adagrasib (Krazati; MRTX849): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Cancers

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

‘Major improvement’: Divarasib extends survival in KRAS G12C-mutated NSCLC

‘Major improvement’: Divarasib extends survival in KRAS G12C-mutated NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC

ESMO: PFS, OS Extended With Divarasib in KRAS G12C-Mutated Advanced NSCLC

ESMO: PFS, OS Extended With Divarasib in KRAS G12C-Mutated Advanced NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC